Clinical Trials Logo

Bipolar Disorder clinical trials

View clinical trials related to Bipolar Disorder.

Filter by:

NCT ID: NCT04325100 Completed - Schizophrenia Clinical Trials

Intervention Targeting Motivational Negative Symptoms

Switch
Start date: April 20, 2019
Phase: N/A
Study type: Interventional

This study aims to investigate the effects of the Switch intervention on motivation and associated processes and explore the dynamics between the processes. A single case approach is followed, with a pre-post and follow-up assessment design, and continuous ambulatory assessments (experience sampling method (ESM) and step count).

NCT ID: NCT04317859 Recruiting - Bipolar Disorder Clinical Trials

Behavioural Activation Therapy for Bipolar Disorder

Start date: May 7, 2019
Phase: N/A
Study type: Interventional

Mood disorders including bipolar disorder and depression are common disabling disorders with depression affecting 11.2 to 16.0% of the general population and the lifetime prevalence of bipolar disorders at an estimated 4.4%. Although treatment with antidepressants medications is common and effective in some patients, 42.7% of patients show inadequate response to treatment with antidepressants and a large proportion (55.3%) continue to have ongoing depressive symptoms. Psychological and behavioural interventions such as cognitive behavioural therapy (CBT) and behavioural activation (BA) are effective treatment for depression alone or in combination with antidepressants. Depression can also occur in the context of bipolar disorder which is characterized by recurrent episodes of depression and mania (DSM-5). The depressive episodes within bipolar disorder may be similar to depressive disorder, however the management of these episodes is fraught with the challenge that antidepressant pharmacotherapy may precipitate manic episodes and lead to further destabilization of bipolar disorder. Therefore, an alternative to antidepressants and additional therapies are needed to support patients' recovery and mood stability, as well as to achieve better treatment response and remission. BA is not currently available in a structured format and has not been tested for its effectiveness in bipolar disorders in a specialized hospital-based program. The evidence for BA has been investigated in depression however the evidence for bipolar disorder is lacking, therefore this study aims to assess the effectiveness of BA as treatment for bipolar disorder.

NCT ID: NCT04304417 Completed - Bipolar Disorder Clinical Trials

The Role of Group Identity on the Community Integration of People With Severe Mental Disorder

Start date: February 17, 2020
Phase:
Study type: Observational

This study analyzes which variables enhance or hinder community integration among people with severe mental disorder. Participants will complete a questionnaire to test our hypotheses: - Hypothesis 1: group identification predicts less self-dehumanization and self-stigma, and more empowerment, these in turn predict more community integration. - Hypothesis 2: the relationship between group identification and self-dehumanization and self-stigma is moderated by group value. - Hypothesis 3: when group identification is low, group identification predicts higher community integration, but this relationship is mediated by diagnosis concealment.

NCT ID: NCT04298450 Recruiting - Schizophrenia Clinical Trials

ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention

Start date: September 21, 2020
Phase: N/A
Study type: Interventional

Psychosis is a disabling condition that typically has its onset in adolescence and early adulthood. Many young people with psychosis have difficulty navigating services or are reluctant to engage in treatment until their illness becomes an emergency. Consequently, nearly half of all new psychotic disorders are diagnosed in the emergency department (ED). Despite the rationale and evidence for early psychosis intervention (EPI), around half of youth do not access these services. The investigators will use short message service (SMS)/text messaging, a low-cost, low-complexity, youth-friendly approach, to improve transitions in care from the ED and related acute services to EPI services, investigating the intervention's effect on attendance at the first consultation appointment, longer term service engagement, and system-level outcomes. The investigators will also evaluate cost-effectiveness and user perspectives of the intervention.

NCT ID: NCT04296604 Recruiting - Schizophrenia Clinical Trials

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

Start date: September 2014
Phase: N/A
Study type: Interventional

In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.

NCT ID: NCT04285515 Completed - Clinical trials for Major Depressive Disorder

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Start date: February 27, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or major depressive disorder (MDD) who also meet the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for mixed-features. The study consists of a Screening Period, a Double-blind Treatment Period, and a Safety Follow-up Period.

NCT ID: NCT04284813 Completed - Schizophrenia Clinical Trials

Families With Substance Use and Psychosis: A Pilot Study

Start date: September 24, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine (video conferencing). The intervention aims to improve treatment engagement and reduce distress, and it will be delivered via telemedicine (CRAFT-FT). To assess feasibility of the intervention, family members will complete the sessions and provide feedback to refine the treatment manual. Data on client relatives with psychosis will be collected for preliminary assessment purposes. Client relatives will not complete the research study intervention.

NCT ID: NCT04284267 Recruiting - Bipolar Disorder Clinical Trials

Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The investigators are conducting this research study to better understand how individuals with bipolar disorder regulate their emotions, and if transcranial magnetic stimulation (TMS) can help improve emotion regulation for individuals with bipolar mood disorders.

NCT ID: NCT04283188 Completed - Bipolar Disorder Clinical Trials

12-Month Extension Study of Dialectical Behavior Therapy for Youth With Bipolar Disorder

DB2
Start date: February 19, 2020
Phase: N/A
Study type: Interventional

The overarching goal of this project is to evaluate the longer-term effects of implementing DBT for adolescents with BD in a subspecialty clinic. In collaboration with the University of Pittsburgh and continuing from the parent study (042-2018), this study will measure the longer-term effects of DBT in additional the the longer-term effects of DBT training on study therapist knowledge and performance.

NCT ID: NCT04276883 Completed - Bipolar Disorder Clinical Trials

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

SERENITY II
Start date: February 24, 2020
Phase: Phase 3
Study type: Interventional

This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with bipolar disorder.